{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:06:29Z","timestamp":1779858389906,"version":"3.53.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.amjmed.2025.07.020","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T06:30:46Z","timestamp":1753857046000},"page":"50-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brand-names and higher-cost generics drive avoidable Medicare Part D expenditures: A quantitative analysis using ACEis and ARBs as a model"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3653-1044","authenticated-orcid":false,"given":"Ji Mei May","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Reiffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Kowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2025.07.020_bib0001","unstructured":"Centers for Medicare & Medicaid Services. NHE Tables (ZIP); Table 1 - National Health Expenditures; Aggregate and Per Capita Amounts, Annual Percent Change and Percent Distribution: Selected Calendar Years 1960-2023. CMS.gov. Updated December 18, 2024. Accessed May 8, 2025. https:\/\/www.cms.gov\/data-research\/statistics-trends-and-reports\/national-health-expenditure-data\/historical."},{"key":"10.1016\/j.amjmed.2025.07.020_bib0002","unstructured":"Centers for Medicare & Medicaid Services. National Health Expenditures by type of service and source of funds, CY 1960-2023 (ZIP). CMS.gov. Updated December 18, 2024. Accessed May 27, 2025.https:\/\/www.cms.gov\/data-research\/statistics-trends-and-reports\/national-health-expenditure-data\/historical."},{"key":"10.1016\/j.amjmed.2025.07.020_bib0003","unstructured":"Cubanski J, Neuman T. What to Know about Medicare Spending and Financing. Kaiser Family Foundation. January 19, 2023. Accessed May 28, 2025. https:\/\/www.kff.org\/medicare\/issue-brief\/what-to-know-about-medicare-spending-and-financing\/."},{"issue":"4","key":"10.1016\/j.amjmed.2025.07.020_bib0004","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1377\/hlthaff.2012.0920","article-title":"Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs","volume":"32","author":"Kanavos","year":"2013","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"10.1016\/j.amjmed.2025.07.020_bib0005","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/jama.2016.11237","article-title":"The high cost of prescription drugs in the United States: Origins and prospects for reform","volume":"316","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2025.07.020_bib0006","doi-asserted-by":"crossref","first-page":"l4257","DOI":"10.1136\/bmj.l4257","article-title":"Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis","volume":"366","author":"Li","year":"2019","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.amjmed.2025.07.020_bib0007","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamadermatol.2018.3798","article-title":"Association between market competition and prices of generic topical dermatology drugs","volume":"154","author":"Li","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.amjmed.2025.07.020_bib0008","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/M16-1432","article-title":"High generic drug prices and market competition: A retrospective cohort study","volume":"167","author":"Dave","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2025.07.020_bib0009","unstructured":"Centers for Medicare & Medicaid Services. Medicare Part D spending by drug. Data.CMS.gov. Updated June 13, 2024. Accessed May 20, 2025.https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-d-spending-by-drug."},{"key":"10.1016\/j.amjmed.2025.07.020_bib0010","unstructured":"Centers for Medicare & Medicaid Services. Medicare Monthly Enrollment. Data.CMS.gov. Updated April 14, 2025. Accessed May 26, 2025. https:\/\/data.cms.gov\/summary-statistics-on-beneficiary-enrollment\/medicare-and-medicaid-reports\/medicare-monthly-enrollment."},{"key":"10.1016\/j.amjmed.2025.07.020_bib0011","unstructured":"Centers for Medicare & Medicaid Services. Manufacturer Rebate Summary Report. CMS.gov. Updated September 10, 2024. Accessed May 8, 2025. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Information-on-Prescription-Drugs\/PartD_Rebates."},{"key":"10.1016\/j.amjmed.2025.07.020_bib0012","unstructured":"U.S. Bureau of Labor Statistics. CPI Inflation Calculator. BLS.gov. Accessed May 8, 2025. https:\/\/www.bls.gov\/data\/inflation_calculator.htm."},{"issue":"4","key":"10.1016\/j.amjmed.2025.07.020_bib0013","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1377\/hlthaff.2012.1252","article-title":"Health care cost containment strategies used in four other high-income countries hold lessons for the United States","volume":"32","author":"Stabile","year":"2013","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.amjmed.2025.07.020_bib0014","first-page":"1","article-title":"Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence","volume":"59","author":"Chalkidou","year":"2009","journal-title":"Issue Br (Commonw Fund)"},{"issue":"12","key":"10.1016\/j.amjmed.2025.07.020_bib0015","first-page":"2491","article-title":"Influence of market competition on tetracycline pricing and impact of price increases on clinician prescribing behavior","volume":"137","author":"Barbieri","year":"2017","journal-title":"J Investig Med"},{"key":"10.1016\/j.amjmed.2025.07.020_bib0016","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Estimating Cost Savings from New Generic Drug Approvals in 2022. US Food and Drug Administration. Updated October 17, 2024. Accessed May 20, 2025. https:\/\/www.fda.gov\/aboutfda\/centersoffices\/officeofmedicalproductsandtobacco\/cder\/ucm129385.htm."},{"issue":"7","key":"10.1016\/j.amjmed.2025.07.020_bib0017","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1377\/hlthaff.2009.0424","article-title":"State generic substitution laws can lower drug outlays under Medicaid","volume":"29","author":"Shrank","year":"2010","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"10.1016\/j.amjmed.2025.07.020_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001955","article-title":"The case for reforming drug naming: Should brand name trademark protections expire upon generic entry?","volume":"13","author":"Sarpatwari","year":"2016","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.amjmed.2025.07.020_bib0019","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0002-9149(00)00715-3","article-title":"Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias","volume":"85","author":"Reiffel","year":"2000","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2025.07.020_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00001573-200101000-00004","article-title":"Issues in the use of generic antiarrhythmic drugs","volume":"16","author":"Reiffel","year":"2001","journal-title":"Curr Opin Cardiol"},{"issue":"2","key":"10.1016\/j.amjmed.2025.07.020_bib0021","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pcad.2004.04.005","article-title":"Angiotensin II receptor antagonists: Role in hypertension, cardiovascular disease, and renoprotection","volume":"47","author":"Appel","year":"2004","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"10.1016\/j.amjmed.2025.07.020_bib0022","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0895-7061(99)00237-X","article-title":"Angiotensin II antagonists for hypertension: Are there differences in efficacy?","volume":"13","author":"Conlin","year":"2000","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjmed.2025.07.020_bib0023","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2165\/00044011-200727110-00001","article-title":"Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure","volume":"27","author":"Baguet","year":"2007","journal-title":"Clin Drug Investig"},{"issue":"2","key":"10.1016\/j.amjmed.2025.07.020_bib0024","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pcad.2004.04.003","article-title":"The clinical use of angiotensin-converting enzyme inhibitors","volume":"47","author":"Wong","year":"2004","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.amjmed.2025.07.020_bib0025","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1742-1241.2009.02028.x","article-title":"Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach","volume":"63","author":"Nixon","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"10","key":"10.1016\/j.amjmed.2025.07.020_bib0026","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1503\/cmaj.060068","article-title":"Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure","volume":"178","author":"Pilote","year":"2008","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.amjmed.2025.07.020_bib0027","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.sapharm.2011.03.001","article-title":"Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: a multiple-propensity analysis","volume":"8","author":"Chitnis","year":"2012","journal-title":"Res Soc Adm Pharm"},{"issue":"2","key":"10.1016\/j.amjmed.2025.07.020_bib0028","doi-asserted-by":"crossref","first-page":"102","DOI":"10.7326\/0003-4819-141-2-200407200-00008","article-title":"Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?","volume":"141","author":"Pilote","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2025.07.020_bib0029","doi-asserted-by":"crossref","unstructured":"Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published correction appears in 2000 May 4;342 (18):1376, published correction appears in N Engl J Med 2000 Mar 9;342 (10):748]. N Engl J Med. 2000;342 (3):145-153. https:\/\/doi.org\/10.1056\/NEJM200001203420301.","DOI":"10.1056\/NEJM200003093421023"},{"issue":"6","key":"10.1016\/j.amjmed.2025.07.020_bib0030","doi-asserted-by":"crossref","first-page":"e2554","DOI":"10.1097\/MD.0000000000002554","article-title":"Comparison of the efficacy and safety of different ACE inhibitors in patients with chronic heart failure: A PRISMA-compliant network meta-analysis","volume":"95","author":"Sun","year":"2016","journal-title":"Medicine (Baltimore)"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325004723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325004723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:00:18Z","timestamp":1779858018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934325004723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0002934325004723"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.07.020","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brand-names and higher-cost generics drive avoidable Medicare Part D expenditures: A quantitative analysis using ACEis and ARBs as a model","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}